

# Help your customers learn how to deliver migraine treatment



- Patients should snap the tip, flip the lever, and press against a pinched area of skin
- The abdomen—more than 2 inches from the navel—may be a preferred administration site due to greater subcutaneous space. The thigh is also an approved administration site

Remind patients to read the Patient Instructions for Use provided with their prescription before administering SUMAVEL DosePro and each time they get a refill.

Click here to view full administration video.

## Here is what patients should expect:

#### Sound

There is a popping sound similar to the opening of a soda can, which indicates successful delivery.

## Sensation

Instruct patients that some discomfort may occur upon administration.
Delivery completed within 1/10 second.

#### **Site Reactions**

After an administration with SUMAVEL DosePro, mild and transient bleeding, swelling, erythema, and bruising may occur. No patients withdrew from SUMAVEL DosePro clinical trials due to these effects.

## Sumatriptan

Typical triptan sensations include transient pain, tightness, pressure, and heaviness in the chest, throat, neck, and jaw.

## Click here for full Prescribing Information.

## **INDICATION and IMPORTANT LIMITATIONS**

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.

## **IMPORTANT SAFETY INFORMATION**

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan. SUMAVEL DosePro should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation.

Serious cardiovascular events, including death, have been reported when taking sumatriptan, including patients with no findings of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cerebrovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL DosePro if a headache being experienced is atypical.

SUMAVEL DosePro should not be used within 24 hours of other ergotamine-containing or ergot-type medications or other 5-HT<sub>1</sub> agonists and is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL DosePro, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy only if the potential benefit justifies the potential risk.

In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/sedation and headache.

## Reference

1. Data on file. Zogenix Inc.; San Diego, CA.

